Vortioxetine hydrobromide inhibits the growth of gastric cancer cells in vivo and in vitro by targeting JAK2 and SRC

Vortioxetine hydrobromide inhibited GC cell proliferation in vitro;Vortioxetine hydrobromide directly bound with JAK2 and SRC;Vortioxetine hydrobromide inhibited STAT3 signaling pathway by targeting JAK2 and SRC kinases;JAK2 or SRC knockout suppressed GC cell proliferation and reduced the sensitivity of GC to vortioxetine hydrobromide